8-K: VivoSim Labs Emerges from Stealth Mode, Targeting $10B+ Animal Testing Market with Novel NAM Technologies

VivoSim Labs, Inc. (Nasdaq: VIVS) emerges from stealth mode to disrupt the drug discovery and development market with its new approach methodologies (NAM) models, capitalizing on the FDA's initiative to phase out animal testing.

Summary

• VivoSim Labs, formerly Organovo Holdings, Inc., has announced its emergence from stealth mode, focusing on providing technologies for the FDA's shift away from animal models in drug testing.
• The company aims to disrupt the >$10B animal testing market by offering liver and intestinal toxicology insights using its new approach methodologies (NAM) models.
• VivoSim's models include physical organoid wet lab models of liver and intestine made using cells from human donors.
• The company is developing in silico predictions of liver tox, intestinal tox, and permeability, trained on proprietary, real-world data from organoid models made from human donor cells.
• VivoSim believes it can help reduce the cost of development per approved drug by 50% across the industry by substantially reducing failures in clinical trials.
• The company's NAMkind liver model has shown an industry-best correlation rate with known clinical failures in development testing.
• VivoSim aims to cut the incidence of drugs failing clinical trials due to unforeseen liver toxicity by 50% or more.
• VivoSim's NAMkind intestine models can deliver readouts that are currently unavailable, potentially improving cancer patient outcomes and chemotherapy dosing.
• The FDA's goal to phase out animal testing requirements is expected to accelerate VivoSim's market adoption.
• The company's new website is now accessible.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook due to the company's emergence from stealth mode, its focus on a growing market, and the potential for significant impact on drug development. The FDA's support further strengthens the positive sentiment.

Positives

• VivoSim is positioned to capitalize on the FDA's initiative to phase out animal testing.
• The company's NAM models offer a more predictive and ethically sound alternative to animal testing.
• VivoSim's technology has the potential to significantly reduce drug development costs and improve patient outcomes.
• The company's NAMkind liver model has demonstrated strong performance in predicting liver toxicology.
• VivoSim's intestine models can provide valuable readouts currently unavailable to industry scientists.

Risks

• The success of VivoSim depends on the continued support and implementation of the FDA's initiative to phase out animal testing.
• The company faces competition from other companies developing NAM technologies.
• The accuracy and reliability of VivoSim's models need to be validated through further testing and real-world application.
• The company's ability to achieve its goals depends on its ability to secure funding and attract talent.

Future Outlook

VivoSim aims to transform drug development by reducing clinical trial failures, lowering development costs, and providing better solutions for patients through its NAMkind models.

Management Comments

• FDA Commissioner Martin A. Makary M.D., M.P.H. stated: 'This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use.'
• FDA Commissioner Martin A. Makary M.D., M.P.H. stated: 'By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices.'
• The technology exists to achieve this according to FDA Commissioner Makary's vision.
• VivoSim is delivering on the promise of this vision, and will use its proprietary methods and cutting edge capabilities for NAMkind models that displace use of animals and provide superior outcomes for its pharmaceutical customers, ultimately delivering for on the end goal of providing better solutions for patients.

Industry Context

The announcement aligns with the broader industry trend towards adopting non-animal testing methods and leveraging AI and human data to improve drug discovery and development processes.

Comparison to Industry Standards

• VivoSim's NAMkind liver model produced liver toxicology results across a wide set of positive and negative control compounds that resulted in an industry best correlation rate with known clinical failures.
• The company believes it can help reduce the cost of development per approved drug by 50% across the industry by substantially reducing failures in clinical trials.
• VivoSim aims to cut the incidence of drugs failing clinical trials due to unforeseen liver toxicity by 50% or more.

Corporate Governance

Stakeholder Impact

• Shareholders may benefit from the company's focus on a high-growth market and its potential to increase shareholder value.
• Employees may benefit from the company's growth and expansion.
• Pharmaceutical customers may benefit from the company's NAM models, which offer a more predictive and ethically sound alternative to animal testing.
• Patients may benefit from the company's technology, which has the potential to accelerate the development of safer and more effective treatments.

Key Dates

Keywords

VivoSim Labs, NAM, animal testing, drug discovery, drug development, FDA, toxicology, organoid models, AI, liver, intestine